Morgan Stanley
BCTXW

Morgan Stanley’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Morgan Stanley’s Portfolio BCTXW Stock Details BCTXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,752
Closed -$51K – 7975
2021
Q3 		$51K Hold
10,752
– – ﹤0.01% 6711
2021
Q2 		$19K Buy
+10,752
New +$13.4K ﹤0.01% 7020

Other funds holding BCTXW

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Morgan Stanley's BCTXW Position: Q4 2021 in Review

Morgan Stanley sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q4 2021, closing a stake of 10,752 shares — an estimated $51K sold.

Morgan Stanley first reported a position in BCTXW in Q2 2021 and held it in 2 quarters. The position peaked at $51K in Q3 2021. 5 funds tracked by Wall St. Rank hold BCTXW as of Q4 2021.

  • Morgan Stanley reported no remaining BriaCell Therapeutics Corp Warrant position as of Q4 2021 after selling out during the quarter.
  • Morgan Stanley sold 10,752 BriaCell Therapeutics Corp Warrant shares in Q4 2021, an estimated $51K.
  • Morgan Stanley first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2021 and held it in 2 quarters.
  • Morgan Stanley's BriaCell Therapeutics Corp Warrant position peaked at $51K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q4 2021.

Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.